How We Think - Treatment

These are the posts from the How we think section that have been tagged with Treatment.

To see all tags used in our posts, click here.

Perspective on biotech

Blue Latitude Health | 14th September 2017

In this supplementary issue of Perspective, we reveal the emerging technologies taking the biotech world by storm and ask if the definition of a biotech organisation needs updating

read more

Could ketamine be the next big thing in depression?

Will Frostick | 20th July 2017

Account Executive Will Frostick discusses the established treatment model for depression and its limitations, as well as a new entrant poised to revolutionise the field – ketamine.

read more

Molecules in a particle-based vaccine for cancer therapy

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

Frances Hendry | 19th May 2017

Anne Legendre reviews the scientific rationale behind immunotherapy combinations and Frances Hendry examines how partnerships, co-marketing and positioning drugs will play key roles in shaping the competitive landscape in oncology.

read more

Introducing_orello_Janssen

Using service design to improve patients’ quality of life

Eimear Power | 29th March 2017

Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.

read more

target-precision-medicine-healthcare-professional-darts

Precision medicine and the changing role of the healthcare professional

Ditte Funding | 23rd March 2017

The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of the healthcare professional (HCP) in the patient journey? Associate Consultant Ditte Funding discusses challenges and opportunities.

read more

cockpit-navigation-airplane_Blue-Latitude-Health

The changing role of the expert in healthcare: challenges in customer-centricity

Elisa del Galdo | 8th February 2017

When we talk about customers as experts in healthcare, what we’re really talking about are clinicians. Experts in diagnosis, treatment and clinical care (HCPs) and experts as those who experience the medical condition in their own personal context (patients). Head of Customer Experience Elisa del Galdo talks through how the evolution of the relationship between HCPs and patients is changing the role of the expert in healthcare.

read more

runway-sea-sky_Blue-Latitude-Health

The 2017 trends issue of Perspective magazine is live

Blue Latitude Health | 9th January 2017

In the 2017 trends edition of Perspective magazine, we explore how advances in technology are influencing the future of the expert-patient relationship and the role healthcare businesses can take in supporting and enhancing these interactions at the point of need.

read more

intro-to-manufacturing-biologics-lab-science

Introduction to the manufacturing of biologics

Ditte Funding | 12th December 2016

The last decade has seen the rapid growth of biologics in the pharma market, making them a key sector to watch. With their growing popularity, it’s important to understand the opportunities and threats they present. Associate Consultant Ditte Funding takes us through how biologics are made, what makes them unique, and what it all means for pharma companies.

read more

patient-perspective-living-with-crohns-disease-blue-latitude-health

Living with Crohn's disease: a patient perspective

Victoria Morton | 16th November 2016

Account Executive Victoria Morton explores what it’s like to live with Crohn’s disease as a young person, and investigates what’s being done to tackle the gaps in treatment options for patients.

read more

chessboard-strategy-photo

Marketing strategy in complex environments

Mark Assenti, Kulveer Singh | 19th September 2016

Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines.

read more